Doxazosin labels and packages
| Doxazosin |
|---|
| Doxazosin®, Cardura® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Doxazosin |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Labels and Packages
PRINCIPAL DISPLAY PANEL FOR 1 MG 100s
Representative sample of labeling (see HOW SUPPLIED] section of complete listing): APOTEX CORP.
NDC 60505-0093-0 Doxazosin Tablets, USP1mgRx100 count
 |
PRINCIPAL DISPLAY PANEL FOR 2 MG 100s
Representative sample of labeling (see HOW SUPPLIED section of complete listing): APOTEX CORP.
NDC 60505-0094-0 Doxazosin Tablets, USP2mgRx100 count
 |
PRINCIPAL DISPLAY PANEL FOR 4 MG 100s
Representative sample of labeling (see HOW SUPPLIED section of complete listing): APOTEX CORP.
NDC 60505-0095-0 Doxazosin Tablets, USP4mgRx100 count
 |
PRINCIPAL DISPLAY PANEL FOR 8 MG 100s
Representative sample of labeling (see HOW SUPPLIED section of complete listing): APOTEX CORP.
NDC 60505-0096-0 Doxazosin Tablets, USP8mgRx100 count
 |
References
- ↑ "DOXAZOSIN TABLET [APOTEX CORP.]". Retrieved 7 March 2014.